tetano
Editor, Senior Moderator
Front Cardiovasc Med
. 2021 Mar 15;8:629958.
doi: 10.3389/fcvm.2021.629958. eCollection 2021.
Cardiovascular Disease and COVID-19: Insight From Cases With Heart Failure
Yang Yi[SUP] 1 [/SUP], Yanan Xu[SUP] 2 [/SUP], Haibing Jiang[SUP] 1 [/SUP], Jun Wang[SUP] 3 [/SUP]
Affiliations
Abstract
Recent evidence indicates that a large proportion of deaths from coronavirus disease 2019 (COVID-19) can be attributed to cardiovascular disease, including acute myocardial infarction, arrhythmias and heart failure. Indeed, severe infection increases the risk of heart failure among patients with COVID-19. In most patients, heart failure arises from complex interactions between pre-existing conditions, cardiac injury, renin-angiotensin system activation, and the effects of systemic inflammation on the cardiovascular system. In this review, we summarize current knowledge regarding pathogen-driven heart failure occurring during treatment for COVID-19, the potential effects of commonly used cardiovascular and anti-infective drugs in these patients, and possible directions for establishing a theoretical basis for clinical treatment.
Keywords: Angiotensin (Ang)-converting enzyme 2; COVID-19; cardiac failure; cardiovascular disease; clinical outcomes; therapeutic strategies.
. 2021 Mar 15;8:629958.
doi: 10.3389/fcvm.2021.629958. eCollection 2021.
Cardiovascular Disease and COVID-19: Insight From Cases With Heart Failure
Yang Yi[SUP] 1 [/SUP], Yanan Xu[SUP] 2 [/SUP], Haibing Jiang[SUP] 1 [/SUP], Jun Wang[SUP] 3 [/SUP]
Affiliations
- PMID: 33791346
- PMCID: PMC8005527
- DOI: 10.3389/fcvm.2021.629958
Abstract
Recent evidence indicates that a large proportion of deaths from coronavirus disease 2019 (COVID-19) can be attributed to cardiovascular disease, including acute myocardial infarction, arrhythmias and heart failure. Indeed, severe infection increases the risk of heart failure among patients with COVID-19. In most patients, heart failure arises from complex interactions between pre-existing conditions, cardiac injury, renin-angiotensin system activation, and the effects of systemic inflammation on the cardiovascular system. In this review, we summarize current knowledge regarding pathogen-driven heart failure occurring during treatment for COVID-19, the potential effects of commonly used cardiovascular and anti-infective drugs in these patients, and possible directions for establishing a theoretical basis for clinical treatment.
Keywords: Angiotensin (Ang)-converting enzyme 2; COVID-19; cardiac failure; cardiovascular disease; clinical outcomes; therapeutic strategies.